Aqemia is a next-gen pharmatech company generating one of the world’s fastest-growing drug discovery pipeline. Our mission is to find a massive number of drug candidates that will become the treatments of tomorrow. Central to our mission are our unique quantum and statistical mechanics algorithms we fuel into an artificial intelligence to design optimized molecules at scale. Unlike usual AI-based platforms that need experimental data to train on, Aqemia tackles drug discovery projects from their earliest stage by generating its own data with quantum and statistical physics calculations. This major breakthrough makes it possible to push the limits of pharmaceutical R&D and discover therapeutic molecules more rapidly and with a better chance of success. We are a next-gen pharmatech company, massively scaling drug discovery projects.

Unlike usual AI-based platforms that need experimental data to train on, Aqemia tackles drug discovery projects from their earliest stage by generating its own data with unique quantum physics algorithms from 12 years of research at Oxford, Cambridge and ENS/CNRS. The unprecedented pace - 10000x faster - and accuracy of our physics algorithms enable us to guide efficiently our generative AI to discover innovative drug candidates more rapidly, and scale drug discovery projects as tech projects. Aqemia started in 2019 as a deeptech spin-off from École normale supérieure, with a unique, multi-awarded physics theory in the rough. In only 3 years, the company has grown to an amazing team of 50+ people, built and extended repeatedly collaborations with large pharmaceutical companies, and started its own drug discovery pipeline with multiple projects ranging from hit generation to vivo assays.